Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies
Lumiere Therapeutics has raised more than RMB 100 million (approximately $14 million) in a Pre-A financing round, giving the Chinese gene-editing company fresh capital to push its epigenetic editing programs toward the clinic. The financing was co-led by…
iRegene’s NouvSight001 Cleared for Retinitis Pigmentosa Trials in China and U.S.
iRegene Therapeutics has secured regulatory clearance in both China and the United States to move NouvSight001, its off-the-shelf photoreceptor cell therapy, into clinical development for retinitis pigmentosa (RP), giving the company another opportunity…
Clover Biopharma’s RSV-hMPV-PIV3 Combination Vaccines Deliver Encouraging Phase 2 Results in Older Adults
Clover Biopharmaceuticals has reported positive preliminary Phase 2 data for SCB-1022 and SCB-1033, two next-generation combination respiratory vaccines designed to protect older adults against multiple major respiratory viruses with a single shot. The…
ApicHope’s AR882 Beats Febuxostat in China Phase 3 Gout Trial, Meeting Primary Endpoint
China’s ApicHope Pharmaceutical Group has reported positive topline results from a Phase 3 clinical trial of AR882 (pozdeutinurad), its next-generation URAT1 inhibitor for gout, showing statistically significant superiority over febuxostat in lowering…
AIPher Raises ~RMB 100 Million Angel Round to Build AI-Native Drug Discovery Platform
Chinese AI-driven drug discovery startup AIPher has completed an angel financing round of approximately RMB 100 million (about $14 million+), an unusually large early-stage raise completed just over a month after the company was established. The…
China NMPA Clears Five Novel Drugs and Two New Indications in September Approval Wave
China’s National Medical Products Administration (NMPA) delivered another busy round of regulatory decisions in early September 2026, clearing a group of innovative therapies spanning oncology, infectious disease, cardiovascular medicine, hematology and…
Simcere Zaiming Out-Licenses SIM0660, a Tri-specific T-cell Engager, to Roche in $1.53 Billion Global Deal
Simcere Zaiming, the oncology-focused subsidiary of China’s Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for SIM0660, a preclinical tri-specific T-cell engager targeting CD79a, CD19 and CD3. The…
2026 China Healthcare Decision-Makers Conference (CHDC)
Every step forward in corporate competitiveness begins with the judgment and leadership of decision-makers. From target selection and technology platform choices to product portfolio decisions, clinical development strategies, BD transactions, market…
ALLYRNA Raises Over RMB 100 Million to Advance RNA Epigenetics-Based Cancer Drug Pipeline
Shanghai-based ALLYRNA has raised more than RMB 100 million in Seed+ financing to advance a new generation of small-molecule cancer therapies derived from RNA epigenetics, including potential radiotherapy and immunotherapy sensitizers for…
Convergen Closes $15 Million Financing to Advance Novel Protein Degradation Therapies for Neurodegenerative Diseases
Suzhou-based Convergen has secured $15 million in Seed+ financing to advance its next-generation targeted protein degradation platform and pipeline for neurodegenerative diseases, as the Chinese biotech seeks to translate its TRIM21-based approach for…